Jun 16, 2020
Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer
Dec 04, 2019
Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2024 - Therapeutics by HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors and Hormone Receptors
Nov 29, 2019
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication
Sep 29, 2019
Novartis Kisqali® delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
Jul 30, 2019
Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
May 07, 2019
2025 Outlook for the Global Breast Cancer Therapeutics Market
Dec 18, 2018
Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis
Nov 29, 2018
Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS
Jul 18, 2018
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Feb 26, 2018
Lilly Receives Additional FDA Approval for VerzenioTM (abemaciclib), as Initial Treatment for Advanced Breast Cancer